Adaptive Biotechnologies Goodwill and Intangible Assets 2018-2024 | ADPT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adaptive Biotechnologies goodwill and intangible assets from 2018 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Adaptive Biotechnologies Goodwill and Intangible Assets 2018-2024 | ADPT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adaptive Biotechnologies goodwill and intangible assets from 2018 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$150.5B
Bristol Myers Squibb (BMY)	$118.1B
Vertex Pharmaceuticals (VRTX)	$115.4B
Gilead Sciences (GILD)	$109.4B
CSL (CSLLY)	$85.4B
Regeneron Pharmaceuticals (REGN)	$81.8B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$34.4B
Alnylam Pharmaceuticals (ALNY)	$30.2B
BioNTech SE (BNTX)	$25.5B
Biogen (BIIB)	$22.6B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$18.3B
Moderna (MRNA)	$14.3B
Incyte (INCY)	$13.6B
Genmab (GMAB)	$13.6B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.8B
Vaxcyte (PCVX)	$10.9B
Bio-Techne Corp (TECH)	$10.5B
Sarepta Therapeutics (SRPT)	$10.2B
Exact Sciences (EXAS)	$10B
Exelixis (EXEL)	$9.8B
Revolution Medicines (RVMD)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
QIAGEN (QGEN)	$9.3B
Intra-Cellular Therapies (ITCI)	$8.8B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$7.5B
Repligen (RGEN)	$7.2B